ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap® (Gliovac...